TransMedics Group (TMDX)
(Delayed Data from NSDQ)
$138.97 USD
-4.83 (-3.36%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $140.00 +1.03 (0.74%) 7:58 PM ET
1-Strong Buy of 5 1
F Value B Growth C Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$138.97 USD
-4.83 (-3.36%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $140.00 +1.03 (0.74%) 7:58 PM ET
1-Strong Buy of 5 1
F Value B Growth C Momentum C VGM
Zacks News
Neogen Suffers From Competitive Pressure, Macroeconomic Woes
by Zacks Equity Research
NEOG faces intense competition, which could affect the marketability and profitability of its products.
ABT Expands Pure Bliss Line of Products for Advanced Infant Nutrition
by Zacks Equity Research
Abbott announces the expansion of its Pure Bliss by Similac line of products for infant nutrition with Organic and Organic A2 Milk infant formulas.
Is It Apt to Hold Globus Medical Stock in Your Portfolio Now?
by Zacks Equity Research
GMED's robust prospects in the musculoskeletal field and the synergies from the NuVasive merger bode well. Yet, macroeconomic issues can affect performance.
Quest Diagnostics Expands in North America With New Acquisition
by Zacks Equity Research
DGX acquires 100% of LifeLabs from OMERS, at approximately $1 billion. It will help LifeLabs to improve healthcare for Canadians.
Reasons to Retain QIAGEN Stock in Your Portfolio Now
by Zacks Equity Research
Investors remain optimistic about QGEN due to its progress in test menu expansion and impressive prospects within its molecular diagnostics segments.
Ekso Bionics (EKSO) Addressable Market to Grow on CMS Update
by Zacks Equity Research
The CMS reimbursement is pivotal for Ekso Bionics (EKSO), as it opens up substantial opportunities in a market where cost has often been a barrier to access
Take the Zacks Approach to Beat the Markets: Vista Gold, TransMedics, Accenture in Focus
by Santanu Roy
Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.
Reasons to Retain ICON (ICLR) Stock in Your Portfolio Now
by Zacks Equity Research
Investors remain optimistic about ICON (ICLR) due to its commitment to patient access and impressive strategic pacts.
SI-BONE (SIBN) Receives FDA Nod for Its TNT Implant System
by Zacks Equity Research
SI-BONE (SIBN) receives FDA 510(k) clearance for its iFuse TORQ TNT implant system, followed by a Breakthrough Device Designation award by the FDA.
Microbot Medical (MBOT) Inks New Phase 2 Agreement for LIBERTY
by Zacks Equity Research
Microbot Medical (MBOT) signs a Phase 2 collaboration agreement with Corewell Health to advance remote telesurgery for endovascular procedures using LIBERTY.
Henry Schein (HSIC) Hurt by Macroeconomic Woes, Cyber Attacks
by Zacks Equity Research
With sustained macroeconomic pressure, Henry Schein (HSIC) struggles to keep in check its cost of revenues and operating expenses.
Should You Hold Labcorp (LH) Stock in Your Portfolio Now?
by Zacks Equity Research
Labcorp's (LH) slew of partnerships and acquisitions and robust efforts in high-growth areas bode well.
Reasons to Retain Bio-Rad (BIO) Stock in Your Portfolio Now
by Zacks Equity Research
Bio-Rad's (BIO) robust digital PCR business and Clinical Diagnostics segments raise optimism. However, macro issues raise concerns.
Globus Medical's (GMED) Lateral Interbody Portfolio Gets New Launch
by Zacks Equity Research
Globus Medical's (GMED) lateral interbody portfolio gets its first commercial product launch with ADIRA XLIF Plate System.
Reasons to Retain Thermo Fisher (TMO) in Your Portfolio Now
by Zacks Equity Research
Strategic alliances and impressive product launches bode well for Thermo Fisher (TMO).
Omnicell (OMCL) Introduces Central Med Automation Service
by Zacks Equity Research
Omnicell (OMCL) has come up with a subscription-based solution named Central Med Automation Service. The solution is expected to improve inventory visibility, scalability and patient safety.
Medtronic (MDT) Q1 Earnings Beat, Fiscal 2025 View Narrowed
by Zacks Equity Research
Medtronic (MDT) reports broad-based growth across all major segments, with strong gains in Cardiac Rhythm & Heart Failure, Structural Heart & Aortic, Cranial & Spinal Technologies and Diabetes businesses.
TransMedics Group, Inc. (TMDX) Hit a 52 Week High, Can the Run Continue?
by Zacks Equity Research
TransMedics (TMDX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Should You Hold Hologic (HOLX) Stock in Your Portfolio Now?
by Zacks Equity Research
Hologic's (HOLX) strength in molecular diagnostics and the enriched Breast Health business are encouraging.
NeuroPace (NPCE) Q2 Earnings Beat, '24 Sales View Up
by Zacks Equity Research
NeuroPace's (NPCE) top and bottom lines outpace estimates in the second quarter.
Paragon 28 (FNA) Expands SMART 28 Ecosystem With New Launches
by Zacks Equity Research
Paragon 28 (FNA) strengthens its position in the foot and ankle device market with the launch of the SMART28 Case Management Portal and the SMART Bun-Yo-Matic device.
Haemonetics (HAE) Set to Launch VASCADE MVP XL in US
by Zacks Equity Research
Haemonetics (HAE) expands its VASCADE portfolio with the full market release of the VASCADE MVP XL vascular closure device in the U.S. market.
Should You Hold Edward Lifesciences (EW) in Your Portfolio Now?
by Zacks Equity Research
Edward Lifesciences' (EW) promising TAVR business and the Critical Care divestment move bode well in the long term.
Accelerate Diagnostics (AXDX) Completes WAVE Pre-Clinical Trial
by Zacks Equity Research
Accelerate Diagnostics (AXDX) is confident about WAVE product design and the system's capabilities after the successful completion of the pre-clinical trial.
Why You Should Add Exact Sciences (EXAS) to Your Portfolio
by Zacks Equity Research
Exact Sciences' (EXAS) progress with strategic priority and strong solvency bode well.